Evan David Seigerman

Stock Analyst at BMO Capital

(3.81)
# 913
Out of 5,182 analysts
55
Total ratings
56.25%
Success rate
8.76%
Average return

Stocks Rated by Evan David Seigerman

Disc Medicine
Feb 17, 2026
Maintains: Outperform
Price Target: $120$100
Current: $67.26
Upside: +48.68%
Merck & Co.
Dec 18, 2025
Upgrades: Outperform
Price Target: $82$130
Current: $110.03
Upside: +18.15%
Regeneron Pharmaceuticals
Dec 4, 2025
Maintains: Outperform
Price Target: $725$850
Current: $731.77
Upside: +16.16%
Amgen
Dec 3, 2025
Maintains: Outperform
Price Target: $335$372
Current: $339.57
Upside: +9.55%
Novo Nordisk
Nov 25, 2025
Maintains: Market Perform
Price Target: $50$46
Current: $41.17
Upside: +11.73%
Replimune Group
Nov 3, 2025
Upgrades: Market Perform
Price Target: $2$11
Current: $2.57
Upside: +328.02%
AbbVie
Sep 12, 2025
Maintains: Outperform
Price Target: $215$240
Current: $197.69
Upside: +21.40%
Neurogene
Jun 12, 2025
Maintains: Outperform
Price Target: $22$26
Current: $27.45
Upside: -5.28%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $24$28
Current: $22.67
Upside: +23.51%
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20$10
Current: $10.22
Upside: -2.15%
Maintains: Outperform
Price Target: $83$100
Current: $43.56
Upside: +129.57%
Reiterates: Outperform
Price Target: $33$36
Current: $26.48
Upside: +35.95%
Maintains: Outperform
Price Target: $9$3
Current: $6.20
Upside: -51.61%
Maintains: Outperform
Price Target: $369$396
Current: $874.00
Upside: -54.69%